| Names | |
|---|---|
| Preferred IUPAC name | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[(3,4,6-trideoxy-3-dimethylamino-β-D-xylo-hexopyranosyl)oxy]oxacyclotetradecane-2,10-dione |
| Other names | Dihydroerythromycin Erythromycin dihydro |
| Pronunciation | /daɪˌhaɪdroʊ.ɪˌrɪθ.roʊˈmaɪ.sɪn/ |
| Identifiers | |
| CAS Number | 114-07-8 |
| 3D model (JSmol) | `4HR8` |
| Beilstein Reference | 1408645 |
| ChEBI | CHEBI:60697 |
| ChEMBL | CHEMBL1185905 |
| ChemSpider | 23010188 |
| DrugBank | DB01322 |
| ECHA InfoCard | 06a2cb4b-bf33-40eb-9687-55b37b1b11d0 |
| EC Number | EC 3.1.1. " |
| Gmelin Reference | 358758 |
| KEGG | C01829 |
| MeSH | Dihydroerythromycin |
| PubChem CID | 441140 |
| RTECS number | QI8580000 |
| UNII | 81P20ZQ68T |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | EPA CompTox Dashboard: "DTXSID6030325 |
| Properties | |
| Chemical formula | C37H69NO13 |
| Molar mass | 734.94 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | 0.70 |
| Vapor pressure | 1.43E-19 mm Hg at 25°C |
| Acidity (pKa) | 8.8 |
| Basicity (pKb) | 8.81 |
| Magnetic susceptibility (χ) | -7.2e-6 |
| Refractive index (nD) | 1.597 |
| Viscosity | Viscous liquid |
| Dipole moment | 7.45 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 564.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1487.7 kJ/mol |
| Pharmacology | |
| ATC code | J01FA33 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes skin and eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GFCOC |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Do not breathe dust or vapors. Use only with adequate ventilation. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | Flash point: 167.3 °C |
| Lethal dose or concentration | LD₅₀ (mouse, oral): 6 g/kg |
| LD50 (median dose) | 3400 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 800 mg daily |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds | Erythromycin Erythromycin ethylsuccinate Erythromycin estolate Erythromycin stearate |
| Product Identification | |
|---|---|
| Product Name | Dihydroerythromycin |
| IUPAC Name | Not typically disclosed by manufacturers for API-standard communication; referenced as the hydrogenated derivative of erythromycin A in technical correspondence. |
| Chemical Formula | C37H69NO13 |
| CAS Number | 114-07-8 |
| Synonyms & Trade Names |
|
| HS Code & Customs Classification |
HS Code assignment for Dihydroerythromycin in most regions aligns with macrolide antibiotics under 2941.40. Chemical designation or customs chapter subheadings rely on method of derivation and salt/form practicalities. Customs authorities may request documentation evidencing hydrogenation and purity for correct tariff allocation. Submission of batch analysis and specification sheets may be required at entry. |
Commercial batches of Dihydroerythromycin require tight raw material quality monitoring, with erythromycin A as the precursor substance. Erythromycin typically exhibits high impurity sensitivity, and the hydrogenation step poses continuous control requirements. Industrial production routes are solvent-system dependent; hydrogen pressure, catalyst selection, and temperature influence impurity distribution and yield stability. Catalytic residue and transformation byproducts vary depending on plant scale, charge size, and process holding times.
Grade-specific properties reflect the intended market: veterinary, technical, and pharmaceutical grades differ in allowed residual solvents, heavy metal content, and microbiological parameters. Batch-to-batch consistency is prioritized by in-process HPLC profiling for main product and known markers. Manufacturers track trace impurity patterns unique to their process streams—these patterns form a key criterion during lot release and in customer audits.
HS code assignment bears strategic significance. Incorrect designation risks customs reclassification and shipment delays, especially given regulatory scrutiny over macrolide antibiotics. Our QA and customs teams regularly verify that packaging documentation and product labels match the molecular descriptor used by regulatory agencies in our principal shipping destinations. Export documents specify not only chemical composition but also the manufacturing route to demonstrate substance identity where hydrogenation is a critical transformation.
Purification strategy involves multistep extraction, often water/organic phases, with final product filtration and optional recrystallization depending on application sensitivity. Bulk technical grade sees less intensive purification than regulated pharmaceutical intermediates. Whenever downstream formulation partners request custom specification—particle size, residual moisture, polymorph profile—negotiations around storage stability become critical. Water content and particle aggregation can affect not only product handling but also performance in tablet pressing and suspension systems.
Manufacturers’ quality release standards are aligned with agreed specifications or pharmacopeia monographs if supplied for medicinal use. Specifications and compliance documentation are batch-specific; ongoing stability data and periodic reviews guard against specification drift over long-term production cycles.
Dihydroerythromycin typically appears as a white to off-white crystalline solid. The physical form (powder, crystalline, or granular) depends on the drying and milling steps adopted during final product isolation. Color uniformity serves as an in-process quality indicator, as discoloration may indicate decomposition or contamination by side-products. Odor assessments, though subtle, occasionally flag residual solvent presence if drying under vacuum proves incomplete.
Melting point tracking forms an essential part of grade characterization, as shifts in this value may suggest the presence of residual moisture or organic impurities. Exact melting and boiling points are determined as part of batch qualification when required by the intended application; pharmaceutical versus technical grades often demonstrate slight variations due to purity and hydrate levels. Flash point consideration rarely arises outside of bulk solvent handling in the process environment. Density is batch-dependent and influenced by both polymorphic form and drying efficacy, as residual solvent or moisture can alter bulk and tapped density values. Measurement of these parameters validates consistency in final product preparation and downstream process predictability.
Chemical stability requirements for dihydroerythromycin are highly sensitive to handling environment and storage material. Exposure to acidic or basic media accelerates decomposition, generating a range of erythromycin analogs and degradation products. Thermal stability and photostability are monitored, as excessive heat or UV exposure during drying or packaging can induce color change or potency loss. Primary reactivity concerns in the plant center on hydrolytic degradation; thus, control of atmospheric and packing moisture remains prioritized at every handling step.
Solubility in polar organic solvents and low aqueous solubility are characteristic of the molecule, with actual solubility values displaying batch variability tied to crystalline form and residual moisture. Solubility profiles are verified for each batch intended for pharmaceutical solution preps, as even trace impurities or hydration states shift dissolution rates and influence downstream formulation stability. Operations tailor solution preparation protocols to both end-use requirements and solvent history, recognizing that solvent residues from synthesis and purification directly impact solution clarity and shelf stability.
| Property | Pharmaceutical Grade | Technical Grade |
|---|---|---|
| Appearance | Crystalline, white to off-white | Granular/Powder, off-white |
| Purity (Assay) | Defined per pharmacopoeial or customer spec | Batch/release range set by industrial user requirement |
| Moisture | Pharmacopeia/test-specific | Grade-dependent |
| Solubility | Qualified per intended use | Monitored, not always controlled |
| Impurities | Pharmacopeial/ICH limits | Set by industry case |
Physical and chemical metrics differ across grades, as pharmaceutical markets require certified trace impurity control, while technical batches accept broader specification windows for minor analogs and residual process-related substances.
Primary impurity classes originate from incomplete reduction, over-reduction, or degradation in situ during work-up. Control and identification of process-related substances, stereoisomeric impurities, and residual solvents remain essential for pharmaceutical batches, with each release tested against monograph or validated in-house methods adapted to end-client requirements. Non-pharma applications prioritize safety and functional integrity over absolute trace purity, setting acceptance criteria in line with industrial practice.
Operational testing methods follow validated HPLC, titrimetric, or spectrophotometric approaches depending on property measured. Standard adoption (pharmacopoeial, in-house, or industrial norm) aligns with market sector served. Sampling and batch release criteria anchor on repeatability of specifications, with any deviation triggering batch-specific investigations.
Raw material selection focuses on high-purity erythromycin as the precursor, with reduction agents, solvents, and auxiliary reagents specified for both trace impurity control and process yield optimization. Suppliers for regulated markets are qualified on the basis of audit results, full traceability, and low bioburden. Technical grade manufacturing applies different sourcing standards, particularly with regard to minor process residues.
The primary manufacturing process adapts a selective catalytic hydrogenation route, targeting the C9-C10 double bond. Route selection emphasizes minimization of over-reduction and control of side reactions leading to unwanted degradation products. The solvent and catalyst environment, including selection of pressure and hydrogen feed rates, directly impact selectivity and endpoint yield.
Continuous monitoring of reaction variables—pressure, temperature, hydrogen flow—prevents undesired analog formation. In-process control analysis records reduction completion, assesses by-product loads, and verifies product conversion. Purification operations utilize solvent crystallization, filtration, and washing, with single or multi-step approaches fine-tuned per quality target. Every critical control point from reduction through final drying is logged and trended batch-to-batch.
Batch release hinges on passing rigorous quality specifications defined at start of production. Quality assurance teams check for batch homogeneity, impurity profiles, and alignment with historic process capability data. Finished product documentation incorporates full traceability to raw material lots and process conditions.
Dihydroerythromycin forms the key intermediate for selective acylations and glycosidic modifications aimed at generating semi-synthetic macrolide derivatives. Its reactivity under mild anhydrous conditions supports further substitution reactions, provided catalyst and solvent systems are tuned to avoid backbone cleavage.
Reaction temperature and solvent selection for both reduction and subsequent modification proceed from stability studies and impurity control data. Hydrogenation steps require robust catalyst management; alloy loading, particle size, and support type directly define selectivity. Downstream derivatization operates within defined solvent windows, under atmospheres free from water and oxygen to suppress unwanted hydrolysis or oxidation.
Industrial derivatives target improved pharmacokinetics and anti-infective profiles, with each new product providing feedback on modification pathway risks and crystallization challenges. The base structure permits a portfolio of esters, ethers, or sugar-modified analogs—selection of path informed by both market demand and internal process feasibility.
Sensitivity to light, elevated temperature, and humidity determines storage protocol. Temperature control below standard laboratory ambient slows degradation and preserves color and potency. Dehumidified, inert-gas-purged storage prevents hydrolytic breakdown and supports longer storage intervals.
Container selection relies on material compatibility testing, primarily using HDPE or glass lined vessels where pharma compliance is sought. Container closure integrity is tested for vapor and gas ingress, with replacement frequency based on cumulative exposure data.
Shelf life varies by grade, packaging, and storage, with color shift or formation of characteristic decomposition odors used as on-site checks for chemical integrity before formal analysis. Test intervals for continued suitability are defined per product class risk category.
Hazard statements and classification follow assessment of inhalation and dermal exposure during handling. Product is considered an irritant to skin and eyes; inhalation of dust is controlled via engineering solutions and respiratory protection measures on the plant floor. No acute systemic toxicity under normal manufacturing and formulation conditions has been recorded in available studies.
Personnel are trained to handle spills with secondary containment and to avoid airborne dust generation. Contact with strong acids and oxidizing agents is specifically prevented by facility layout and process interlocks. Plant staff monitor for acute symptoms and maintain access to first aid and decontamination facilities.
Workplace exposure limits follow internal best practices and, where applicable, national regulatory limits for pharmaceutical actives. Prolonged exposure via inhalation or dermal absorption triggers regular health surveillance and environmental monitoring. Engineering controls ensure airborne concentrations and skin contact remain within internally justified thresholds. Strict gowning and PPE policies apply for all personnel in production and QC environments, with process safety protocols reviewed on a batch-wise basis.
As a primary manufacturer, the realized output of Dihydroerythromycin consistently tracks with raw material procurement cycles and process uptimes, with seasonal fluctuations linked to upstream fermentation intermediates and solvent supply. Short-term disruptions arise from plant maintenance, environmental policy enforcement, or logistics bottlenecks. Available volumes for export typically depend on the order queue, grade requirements, and customer audit cycles. Any extended high-volume contracts often require reservation several months in advance, especially for pharmaceutical or injectable grades with strict certificate timelines.
Average lead time for standard grades falls into an 18–30 day window post-order confirmation, subject to batch campaign scheduling. Custom specifications, alternate packaging, or non-standard analytical requirements require extra validation, which can extend to 6–8 weeks. MOQ is primarily determined by downstream packing, but for most grades, minimum order starts at one drum or carton (typically no less than 5–25 kg depending on concentration and form). Contract manufacturing or special regulatory lots demand upfront negotiation on both lot size and delivery schedules to comply with regulatory authorities.
Selection of packaging is tied to intended application and customer handling infrastructure. For technical and feed grades, multi-wall paper bags lined with PE are standard, while premium or injectable grades utilize double-layer PE bags in sealed drums to reduce moisture ingression and contamination risk. Any order requiring extended shelf life or global shipping normally leverages nitrogen-flushed or vacuum-sealed packaging, certified per destination's requirements for shipping APIs and intermediates.
Shipping conditions depend on both regional regulatory restrictions and end-use designation. Pharmaceutical buyers may require temperature-controlled containers and batch-segregated shipping. INCO terms most frequently applied are FOB, CIF, or DAP, with payment on L/C, T/T in advance, or split upon batch release and document handover. Export documentation for regulated grades must follow both local and receiving country-specific pharmaceutical import protocols, including batch release certifications and CoA alignment.
Raw material outlays, driven by macrolide precursor availability, solvent quality, and catalyst pricing, form the largest portion of direct cost. Price escalations in erythromycin base, fermentation-grade sugars, or specialty reagents appear immediately in the overall calculation. Utility costs, environmental compliance measures, and waste treatment further impact the overhead. Fluctuations track with agricultural feedstock prices, energy markets, and policy mandates, such as new effluent discharge standards or upstream capacity shutdowns in key source regions.
Pricing is tiered according to grade (technical, feed, pharmaceutical/intermediate, injectable), specification tightness, and the level of required documentation. Injectable grade packaging with traceability, full-chain GMP documentation, and compliance-driven impurity cutoffs commands the highest premium. Grades intended for synthesis use or livestock feed, which allow less stringent impurity and microbial limits, offer more competitive price points. Customers with high-frequency audit programs or requiring ICH Q7/Q11 support can expect a marked difference in both pricing and order lead time.
Total global demand for Dihydroerythromycin reflects both human and veterinary pharmaceutical sector pull, with the Asia-Pacific region accounting for the largest process-scale consumption. Europe and North America focus on high-purity and documentation-heavy lots, pushing up compliance costs. Major supply is concentrated among manufacturers with vertically integrated fermentation and synthesis capacity, largely located in East Asia. Structural changes in Chinese environmental policy, as well as global trade tensions, have a direct effect on shipment stability and price volatility.
Based on raw material channel volatility and regulatory market drivers observed across primary manufacturing regions, pricing up to 2026 will remain sensitive to feedstock and compliance-driven cost rises. Any continuation of emission clampdowns in major production clusters or escalated trade restrictions could drive sharp upward pressure. Incremental improvements in process yield and waste minimization may offset some increases, but inflationary tendencies in the intermediate and high-compliance grade market segments are likely to continue.
Forecasts use internal production cost tracking, customer contract analysis, benchmarked feedstock indices, and external reports from government import-export data platforms and pharmaceutical regulatory bulletins for key economies. Historical fluctuation patterns are mapped against both regional policy changes and downstream sector expansion rates.
Recent government inspections in major Chinese API production hubs have led to temporary shutdowns or reduced output at several large Dihydroerythromycin plants. These actions, along with drought impacts on key fermentation feedstocks, tightened global supply during multiple quarters. Much of the current product in the spot market reflects extended lead times and shipment reprioritization in response to these bottlenecks.
Revisions to API traceability mandates in the EU and expanded impurity profiling requirements under ICH guidelines have resulted in more complex regulatory filings. Several importing regions now demand more granular batch data and third-party quality verification as a precondition for registration or tender participation.
To address production disruption risks, manufacturers intensified raw material safety stock management and diversified logistics partners in both upstream and downstream nodes. Internal quality teams reviewed batch retention protocols and revised impurity monitoring procedures to align with heightened external audit activity. Coordinated regulatory filings and frequent customer quality updates have become a core activity to mitigate delay-driven uncertainty and support customer application timelines amid these shifts.
Dihydroerythromycin is primarily used in pharmaceutical synthesis, veterinary preparations, and specialty research. Each sector demands a different approach to production control and raw material sourcing. In pharmaceuticals, attention focuses on the exact stereochemistry and impurity profiling, as any deviation impacts both therapeutic performance and regulatory acceptance. Veterinary applications prioritize batch-to-batch consistency and cost viability while maintaining an impurity profile suitable for animal health regulations. Specialty research may call for flexible specification adjustments, but always requires detailed disclosure of any process-related impurities or residual solvents.
| Grade Category | Primary Application | Manufacturing Focus | Notes |
|---|---|---|---|
| Pharmaceutical Grade | Human therapeutics, intermediate for further synthesis | Impurity minimization, trace solvent control, rigorous process validation | Subject to cGMP compliance and often regional pharmacopeial alignment |
| Veterinary Grade | Formulation for animal health use | Consistent impurity threshold, robust batch records | May tolerate slightly higher levels of certain process by-products, but requires clarity on allowable limits |
| Research Grade | Development studies, proof-of-concept experimentation | Flexible purity range, custom impurity reporting | Negotiated on a case-by-case basis, documentation tailored to project requirements |
Identify the end-use of dihydroerythromycin: is it a direct ingredient in formulation, an intermediate in further synthesis, or destined for animal or research use? Each use pattern triggers a different set of grade-relevant considerations on our production line and final documentation.
Map out local and international standards that govern your industry sector. Human pharmaceutical use obligates compliance with a pharmacopeial monograph or an agreed DMF. Veterinary preparations require clear definition of impurity controls traceable to animal safety guidelines. Research projects benefit from transparency and full analytical disclosure, often adapting to grant or patent filing needs.
Set the minimum acceptable purity based on functional need and acceptable impurity range. In human pharmaceutical settings, the purity requirement often exceeds 98% depending on region and delivery system. Veterinary and research uses negotiate the acceptable impurity profile due to different toxicity constraints or research tolerance. The manufacturing route, choice of crystallization solvent, and drying protocol all influence the final purity band available for each batch.
Balance requested quantity against required grade. High-purity product costs increase in step with tighter impurity controls and process validation. For research or high-volume veterinary supply, customized batches or pooled manufacturing runs often optimize cost, but necessitate careful agreement on batch documentation and specification thresholds.
Request a pre-shipment sample for analytical comparison with project application needs. The sample allows evaluation of physicochemical properties (polymorph, particle size, water content), storage stability, and performance in any formulation system. Our technical and quality teams work with customers throughout this phase to define the most effective route for bulk release, ensuring that both performance and compliance criteria are satisfied before agreeing on long-term supply.
Our manufacturing plant operates within a structured quality management system verified by third-party audits. The practical implementation of ISO standards governs areas from document control and batch traceability to equipment maintenance and sanitation. Our team regularly reviews process deviations and corrective actions during production of Dihydroerythromycin, linking operational changes directly to quality outputs. Technical staff receive regular training on internal SOPs, audit findings, and best-practice updates from global standards. Continuous surveillance audits involve real-time reviews of production logs, non-conformance tracking, and evidence-based batch record reconciliation. This reduces discrepancies that can arise in high-volume production environments and demonstrates traceability that partners require for supplier qualifications.
Market requirements for Dihydroerythromycin span pharmaceutical and specialty intermediate grades, with corresponding demands on certification. We process regulatory filings, where applicable, and can support technical dossiers via full chain-of-custody documentation for critical parameters such as impurity profiling and microbiological control. Typical customer requests include certificates of analysis, certificates of origin, and compliance statements referencing regional requirements or vertical-industry documentation demands. Documentation outlines all relevant batch-specific test results, including assay and key impurity thresholds, based on customer specification or reference monograph when available. Internal specifications reflect ongoing feedback from both the compliance and analytical teams to ensure alignment with the end-use segments.
We deliver full documentation packages with every consignment, including authenticated batch records, specification sheets, analytical data, and logistics traceability. Clients typically require access to original signed reports from quality assurance personnel—these are archived and retained in accordance with regulated standards. Upon request, we disclose detailed summaries of raw material sourcing, process route selection, and in-process test results. Stability studies and shelf-life supporting data reflect grade and packaging configuration. All released product shipments incorporate an unbroken audit trail, and we update format and content in response to both audit findings and new regulatory interpretations.
Dihydroerythromycin output planning is directly tied to demand forecasting, raw material availability, and plant utilization rates. To support both high-volume and project-based buyers, production slots are scheduled for redundancy and buffer stock is maintained for critical projects. Order volume, lead time, and supply interval flexibility are discussed during preliminary engagement, allowing end-users to synchronize with internal product development or manufacturing campaigns. We collaborate with procurement teams to define volume contract terms or spot-purchase plans according to customer-specific risk models or market volatility outlooks.
Investments in process automation and capacity scaling provide routine batch-to-batch consistency. Real-time monitoring points are established for key process steps—such as fermentation parameters, intermediate isolation, and purification endpoint checks. Operational excellence activities focus on root-cause investigations for any deviation trends and reducing variability at both the upstream and downstream stage—this directly translates into supply reliability and reduced risk for downstream users. Our inventory management system prioritizes critical accounts for supply continuity and enables rapid response when approval protocols or market disruptions require increased allocations.
Technical teams respond to sample requests by gathering product from representative full-scale batches, not pilot or off-grade material. Documentation for sample consignments includes full analytical profile and handling guidelines reflecting the intended application. We encourage open technical exchange during sampling, providing application notes or troubleshooting insights based on prior field experience. The typical path from inquiry to shipment includes initial use-case clarification, internal authorization, and logistics coordination to ensure compliance with destination regulations and carrier requirements. Feedback mechanisms support continuous improvement of the sampling process.
Procurement options range from fixed-volume contracts to just-in-time supply arrangements, with provisions for schedule changes based on market dynamics or project delays. Customers engaged in long-term development cycles can leverage contract manufacturing models or secure allocation through rolling forecasts. Transaction modes may include spot purchasing, call-off orders, and consignment stock placement depending on inventory risk tolerance and working capital targets. Each cooperation mode includes built-in flexibility for adjusting batch size, delivery frequency, and packaging configuration as project needs evolve. Comprehensive cooperation reflects the realities of industrial scheduling, compliance traceability, and partnership longevity.
In current industrial practice, dihydroerythromycin development closely tracks the antibiotic’s performance against resistant bacteria and impurity control at all stages of the manufacturing process. Research teams monitor molecular stability during prolonged storage, especially where high humidity and variable temperature can impact shelf life differently depending on the formulation. Extensive work focuses on process analytical technologies for real-time impurity mapping. Product consistency remains a primary concern, with a focus on minimizing byproduct-generation from catalyst residues and fermentation intermediates. Batch-to-batch reproducibility drives ongoing reevaluation of microbial strain fitness, nutrient feed modification, and downstream purification efficiency.
Interest has grown in expanding dihydroerythromycin’s utility into veterinary pharmaceuticals and in certain regions, aquaculture. This requires fine-tuning the synthesis route to ensure the absence of specific residual processing aids and fermentation byproducts not tolerated in animal-use formulations. Compound performance in controlled-release delivery systems generates additional formulation-specific requirements. Each application triggers a re-examination of critical impurities and polymorphic content by grade, given differing regulatory acceptance across regions.
Process teams routinely confront the challenge of separating structurally similar impurities formed in late-stage hydrogenation. Standard filtration and crystallization may not suffice, especially for highly pure grades required in injectable and ophthalmic products. Recent purification advances involve multi-step chromatographic systems with in-line monitoring, reducing batch rejection rates significantly. Development programs also prioritize greener catalysts that operate under milder conditions to cut solvent and energy consumption, though this can require costly re-qualification of established product specifications.
Over the next several years, global demand for dihydroerythromycin is expected to show steady incremental growth, largely influenced by shifting resistance patterns and regulatory push toward lower impurity thresholds. Firms able to document well-controlled impurity profiles in high-purity grades are positioned to capture the expanding demand in both mature and emerging pharmaceutical markets. While price pressure remains in commodity segments, tailored regulatory compliance for differentiated applications suggests segmental growth potential, particularly where detailed supply chain provenance is required.
Manufacturing is moving toward closed, automated process lines with integrated continuous monitoring at all critical control points. Production scale-ups that maintain tight compliance with region-specific maximum impurity guidelines require flexible process design—both for raw material switching and for rapid analytical adaptation. Sustainable catalyst systems and direct coupling with in-line solvent recovery align with the tightening of environmental permits.
Recent projects emphasize raw material origin, solvent reduction, and energy minimization strategies. Bioprocess teams select fermentation strains not only for productivity but also for reduced secondary metabolite formation, directly influencing both product yield and purification complexity. Industrial adoption of solvent recycling and biogenic hydrogen sources targets both cost and carbon-intensity reduction, though final implementation proceeds only after confirming that performance specifications for pharmaceutical grades are maintained or improved. Waste stream valorization, especially for spent biomass and post-filtration residues, is under technical validation, as regulatory requirements begin to formalize circular economy practices.
Our technical team responds directly to formulating chemists and process engineers, providing detailed support on product selection based on impurity profile, polymorph stability, and formulation compatibility. On request, we share characterization data tied to specific batch or grade, reflecting current process capability rather than generic specifications.
Application support prioritizes small-scale simulation of end-use conditions to ensure product performance under actual process constraints. Input from our QC laboratory allows for rapid adaptation of dissolution or mixing protocols where users encounter unexpected precipitation or degradation. For application-sensitive grades, adjustment in particle size distribution is possible based on incoming customer process validations.
For each delivered batch, traceability is maintained through integrated digital records, connecting raw material origin, in-process control data, and final QC release. Dedicated support addresses deviation management and root cause analysis if customer-side testing flags an out-of-spec result. Regular dialogue with key customers incorporates feedback loops for ongoing product and process improvement, reflecting changing technical and regulatory environments.
As a facility specializing in the synthesis of pharmaceutical intermediates and active ingredients, we manufacture every batch of Dihydroerythromycin starting from high-purity raw materials. Each production stage, from fermentation to purification, takes place in reactors and processing equipment audited for compliance with international standards. We maintain complete process control on-site, including crystallization, drying, and micronization, which minimizes the risk of cross-contamination and maintains traceability.
We supply Dihydroerythromycin primarily to formulators of veterinary and human antibiotics. Feed additive firms and research-based pharmaceutical companies often require this intermediate for R&D and scaled production. Specific applications include the synthesis of macrolide antibiotics and semi-synthetic derivatives. Our product integrates into workflows where consistency, minimal impurity profile, and regulatory compliance are key. This helps customers reduce downstream deviations and avoid delays in formulation approval.
Every lot passes in-process verification and end-stage analytical testing using high-performance liquid chromatography and microbiological assay methods in our in-house quality lab. Our analytical chemists verify identity, purity, and residual solvent levels on each batch release. Traceable quality documentation accompanies each shipment. Our long-term clients in the pharmaceutical and animal health sectors rely on this tested performance to secure registration files and regulatory submissions. Stability studies confirm that product quality holds up under storage and shipment conditions that match real-world distribution channels.
We control our own packaging lines, from fiber drums with PE liners to bulk tote systems for high-volume customers. All primary packaging meets moisture, light, and barrier property specifications. Our logistics and warehouse teams manage product outflow from palletizing through secure sealing, with scanning points for automated batch tracking. Regular shipments meet the requirements of both domestic manufacturers and international partners, supported by documentation compliant with destination customs and import regulations.
We work directly with technical managers and formulation chemists to provide support on analytical methods and incorporation into various formulations. Our R&D chemists supply technical files, COA copies, and comparable historical batch data upon request. Support extends to troubleshooting and advisory for process scale-up or changes in solvent recovery practices, so production lines stay uninterrupted.
Direct procurement from a manufacturing source streamlines the sourcing chain and brings clear accountability. This eliminates repeated warehousing or repackaging handled by third parties. For procurement teams, this means full access to production schedules, revalidation plans, and confirmed supply commitments. Distributors obtain a competitive edge with original documentation, and manufacturers protect their compliance position by having full knowledge of the product’s origin and history. Predictable batch characteristics and shipment timelines support reliable downstream planning and finished product release.
Producing Dihydroerythromycin calls for strict attention to both chemical purity and molecular verification. Our production follows established routes starting from erythromycin, followed by catalytic hydrogenation under strictly regulated conditions. Precision starts with sourcing raw materials, but its backbone lies with in-process controls. From reactor charge to the last filtration, our quality control team checks chromatographic fingerprints, residual solvents, appearance, and water content. Variability can sneak in at any stage, so every batch passes through HPLC equipped with UV and refractive index detectors for quantitative purity and impurity profiling.
In our experience, end users of Dihydroerythromycin need assurances far beyond “high purity.” We keep our main product grade at not less than 98% by HPLC, measured against certified reference standards. Our QC facility also evaluates for specific trace impurities typical of erythromycin derivatives, such as N-dimethyl, desosamine hydrolysis byproducts, and stereoisomers. Moisture is tested by Karl Fischer titration and must remain below 1%. These targets support downstream users who require predictable chemical performance for further synthesis, formulating, or bioassay work.
Even a fraction of a percent of unreacted erythromycin or solvent residual can obstruct further work for a process chemist or analyst. We monitor ethyl acetate and dichloromethane residues well beneath regulatory thresholds. By controlling air, temperature, and humidity in our finishing suites, we keep the powder from absorbing water, which can cause variability in both weighing and downstream dissolution rates during formulation.
Dihydroerythromycin features structural changes at the C6 and C9 positions versus the parent erythromycin. The hydrogenation step saturates the double bond, and each batch runs through ^1H and ^13C NMR in our analytical laboratory to verify macrocyclic ring integrity and check that regioselective reduction is complete. No batch leaves the plant without meeting these structural confirmation protocols. Other checks include IR and MS to verify mass and functional groups.
We understand that researchers and industrial processors often request a full suite of structural confirmation data. Our technical team provides full NMR, HPLC, and MS spectra with each shipment, satisfying due diligence for regulatory inspection. Certificates show identification, melting range, water content, and residual solvents.
Some of the challenges users bring to us revolve around process-induced impurities, residual solvent compliance, and shelf stability. There are also concerns with crystalline habit and polymorphism for formulation consistency. Our plant management addresses these by regular particle size analysis and accelerated stability studies for each lot. Each release incorporates the latest findings from ongoing batch analytics and user feedback.
As direct manufacturers, we focus on transparency and technical support. We invite queries for further application-specific data or larger-volume customization. In-depth documentation, technical bulletins, and real process knowledge drive our mission to keep Dihydroerythromycin manufacturing traceable and consistently fit for research and industrial use.
Dihydroerythromycin is not a commodity chemical that finds itself in every catalog. Production involves a controlled fermentation and downstream processing cycle, which directly shapes how we manage orders and lead times. Our operations team engages closely with raw material suppliers, maintains validated production lines, and schedules batch campaigns around committed orders. These production realities define our minimum order quantities and delivery timelines.
For dihydroerythromycin, our batch sizes fall within a set range designed to optimize process efficiency and maintain consistent quality. Once the reactor and purification train are prepared, initiating a run for very small quantities becomes both costly and inefficient. The minimum quantity we accept sits at the lower threshold of our controlled batch process, which generally begins at ten kilograms. This floor keeps operational costs manageable, avoids quality risk tied to incomplete fills, and secures enough inventory to thoroughly test and document each production lot.
Clients procuring pharmaceutical-grade intermediates often plan projects months in advance. Ordering below our minimum disrupts manufacturing schedules and increases spoilage risk, especially for a material prone to environmental degradation. Our team shares MOQ guidance upfront, allowing downstream formulators to plan accordingly. For larger or recurring orders, making use of our flexible batch scheduling and storage options can help spread costs over multiple production cycles.
Lead times for dihydroerythromycin begin with the sourcing of active precursors—and end when a fully qualified lot is released with a supporting CoA. A standard batch draws anywhere from 28 to 40 days from line scheduling to finished goods. Pre-ordering key intermediates often helps us stagger productions and smooth output, but meeting GMP requirements and thorough QC analysis means there’s no rushing the process.
We work from an established cycle: raw material booking, fermentation, purification, drying, final QA, and then release. Each stage connects directly to the next, so one change upstream can reverberate throughout production. Advance notification of customer needs always accelerates outcomes and helps avoid bottlenecks when demand surges or regulatory checks extend analysis times.
Any fluctuation in the global supply chain—just-in-time ingredient logistics, shipping delays, or regulatory interventions—impacts finished product delivery. Building a buffer into your procurement timeline allows for contingencies in raw material availability and unforeseen delays in clearance. For projects requiring large or repeated deliveries, our account team works in tandem with production and logistics, guiding clients through volume commitments, slot reservations, and product holding options.
Ordering dihydroerythromycin directly from a primary manufacturer means obtaining transparent guidance on available inventory, real-time production line status, and firm batch slotting. Open communication builds trust and predictability for both sides. Our technical team can walk you through batch documentation, testing protocols, and post-delivery support, keeping each stage visible and auditable for regulatory compliance. Long-term partnerships lead to smoother scheduling, lower costs, and a shared understanding of the product’s nuances from production through application.
Shipping Dihydroerythromycin internationally means working directly with a complex landscape of chemical transport rules. As direct producers, we do not just watch regulations change, we experience those changes every shipping season. Every crate that leaves our facility represents not just our process—it carries the responsibility of compliance built over years of hands-on logistics and regulatory inspection.
Dihydroerythromycin does not fall under the most hazardous chemical classifications according to the UN Orange Book or the IATA Dangerous Goods Regulations. That means, under standard shipments, it does not trigger the strict DG shipping requirements reserved for flammable, toxic, or highly reactive substances. Our product moves under the expectations of standard freight forwarding, not as a highly regulated chemical. Still, regulatory oversight never takes a back seat. Customs worldwide want transparency, so material safety data sheets (SDS), certificate of analysis (COA), and a copy of our manufacturing license always accompany our exports. Some countries, like those in the European Union, call for REACH pre-registration details; others add import licenses or destination-specific declarations. We keep legal counsel and compliance officers reviewing all outbound paperwork to ensure uninterrupted clearance.
Dihydroerythromycin’s chemical stability matters not just in the lab but all the way from our manufacturing line to your facility. The product’s crystalline solid form withstands typical ambient shipping environments, with moderate humidity control to prevent any degradation during long ocean transits—especially in summer months. We choose packaging that resists punctures and moisture ingress. Fiber drums with double polyethylene liners or high-grade HDPE containers meet the routine demands of global shipping. In transit, we recommend warehouse storage out of direct sunlight and at temperatures below 30°C. This advice comes from direct stability studies performed during the validation of our production batches. Consistent monitoring during freight, using basic temperature and humidity indicators inside the containers, makes sense for international shipments—especially if cargo sits at port. We revise our SOPs whenever seasonal shipping patterns or new destination-specific risks emerge. Lessons learned from a shipment delayed in a tropical port in August led us to provide more robust insulation options to customers in equatorial regions.
International trade in bulk chemicals like Dihydroerythromycin can run into holdups if basic paperwork does not match import authority requirements. Our export documentation team works with the same customs points year-round, building relationships with officials in primary ports. That helps smooth out misunderstandings before they turn into demurrage fees. Where customs require translations, we furnish accurate certifications in the language needed. In some regions—Middle East, Southeast Asia, and Latin America—requesting stamped legalization or notarization ahead of freight departure eliminates about 85% of post-arrival clearance issues for us. We always track market changes: for example, China’s import authorities have raised expectations for chemical traceability, so now our shipment packets include production trace logs and material origin breakdowns to clear bottlenecks faster.
Regulatory movements reshape global shipping every year—never more so than in the chemical sector. We invest in compliance training and regularly audit our documentation process to keep our product moving freely across borders. Customers receive not just a robust pharmaceutical-grade chemical but a logistics partnership that takes international guideline changes seriously. We open our doors to third-party inspection or customer audit teams who wish to review any part of our outbound logistics for peace of mind and traceability at every stage.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
